Online citations, reference lists, and bibliographies.

Can Delayed Time To Referral To A Tertiary Level Urologist With An Abnormal PSA Level Affect Subsequent Gleason Grade In The Opportunistically Screened Population?

F. O'kelly, A. Thomas, D. Murray, David Galvin, D. Mulvin, D. Quinlan
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE There is growing conflict in the literature describing the effect of delayed treatment on outcomes following radical prostatectomy. There is also evidence to suggest progression of low-risk prostate cancer to develop higher grades and volumes of prostate cancer during active surveillance. It is unknown as to what affect a delay in referral of those men with abnormal screened-PSA levels have on subsequent Gleason grade. METHODS We identified 350 men through our rapid access prostate clinic who underwent TRUS biopsy for abnormal age-related PSA and/or abnormal clinical examination. Clinicopathological findings were compared for those with positive versus negative TRUS biopsies, and for those with initial delays in referral (<12 months, 12-18 months, and >18 months). We used ANOVA and Student's t-tests amongst other statistical tools to examine significance of clinical findings. RESULTS Of the 350 men who underwent TRUS biopsy, those with a delay in referral of 12 months or more were significantly associated with higher PSA titers, clinically palpable disease and likelihood of diagnosis with prostate cancer. A delay of 18 months or more led to a significantly higher risk of being diagnosed with a leading grade 4 prostate cancer, which was further supported using PSA velocity as a diagnostic tool (change >0.4 ng/ml/year). CONCLUSION We recommend that repeated asymptomatic abnormal age-related PSA readings and/or abnormal clinical examination in the screened population be referred without delay to a urologist for further assessment, enrolment into an active surveillance program or definitive subsequent treatment.
This paper references
10.1111/j.1464-410X.2008.08255.x
Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population‐based study
R. Kvåle (2009)
10.1097/01.JU.0000140277.08623.13
Impact of surgical delay on long-term cancer control for clinically localized prostate cancer.
M. Khan (2004)
10.1016/j.eururo.2012.05.072
Active surveillance for prostate cancer: a systematic review of the literature.
M. Dall’Era (2012)
10.2214/AJR.179.6.1791401
Liability for failure to order screening examinations.
L. Berlin (2002)
10.1016/j.juro.2010.06.008
Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study.
B. Holmström (2010)
10.4065/83.4.439
Prevalence of delayed clinician response to elevated prostate-specific antigen values.
Kenneth G. Nepple (2008)
10.1200/JCO.2008.19.9794
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
M. F. O'Brien (2009)
10.1111/j.1464-410X.2010.09589.x
Surgical management after active surveillance for low‐risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment
M. Dall'Era (2011)
10.1111/j.1464-410X.2011.10900.x
Prostate‐specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer
S. Loeb (2012)
10.1016/j.juro.2011.02.009
Delay of surgery in men with low risk prostate cancer.
D. O'Brien (2011)
10.1002/ijc.22158
Gleason score, age and screening: Modeling dedifferentiation in prostate cancer
G. Draisma (2006)
10.1002/pros.22498
Trends in pathologic outcomes after introduction of active surveillance in the UK: implication for focal therapy.
Markos Karavitakis (2012)
10.1016/S1553-7250(05)31013-0
Failure to recognize and act on abnormal test results: the case of screening bone densitometry.
P. Cram (2005)
10.1016/j.juro.2011.10.156
Impact of distance to a urologist on early diagnosis of prostate cancer among black and white patients.
J. Holmes (2012)
Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy.
R. Nam (2003)
10.1016/S0022-5347(05)00646-4
Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer.
S. Freedland (2006)
10.1111/j.1743-6109.2012.02806.x
Is a treatment delay in radical prostatectomy safe in individuals with low-risk prostate cancer?
M. Sun (2012)
10.1016/J.JURO.2007.03.003
Guideline for the management of clinically localized prostate cancer: 2007 update.
I. Thompson (2007)
10.1111/j.1464-410X.2011.10666.x
Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis
R. Korets (2012)
10.1136/bmj.322.7302.1555
Is the two week rule for cancer referrals working?
R. Jones (2001)
10.1002/ijc.25471
PSA‐detected prostate cancer and the potential for dedifferentiation—estimating the proportion capable of progression
N. Pashayan (2011)
10.1016/S1553-7250(07)33052-3
The continuing problem of missed test results in an integrated health system with an advanced electronic medical record.
T. Wahls (2007)
10.1200/JCO.2010.33.0134
Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance.
S. Porten (2011)
10.1002/cncr.24882
Is delayed radical prostatectomy in men with low‐risk screen‐detected prostate cancer associated with a higher risk of unfavorable outcomes?
Roderick C. N. van den Bergh (2010)
10.1111/j.1464-410X.2012.11045.x
Active surveillance for prostate cancer: an Australian experience
Joseph J. Ischia (2012)
10.1001/JAMA.280.11.969
Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer
A. D'Amico (1998)
10.1002/cncr.21643
Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence?
A. Vickers (2006)
10.1002/pros.22507
Pathological findings at radical prostatectomy in patients initially managed by active surveillance: a comparative analysis.
V. Iremashvili (2012)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar